The Centers for Disease Control and Prevention said around 3.2 million Americans received updated COVID boosters last week. The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people. (Reuters)

The Food and Drug Administration’s accelerated approval pathway has largely been supported by the pharma industry, worrying some medical experts about approved drugs’ efficacy. “We are getting a lot of marginally effective, not clinically meaningful, more expensive drugs on the market,” said Dr. Aaron Mitchell, an oncologist at Memorial Sloan Kettering Cancer Center. (Kaiser Health News)

Pfizer CEO Albert Bourla pulled out of testifying to the EU Parliament COVID panel. High-level contacts between Bourla and European Commission President Ursula von der Leyen before the multibillion-euro vaccine deal are under scrutiny. (Politico)

Recently published studies are beginning to establish a link between fungi and cancer, with researchers identifying fungi in tumors. But the research leaves plenty of scientific questions, such as what the fungi are doing there, and how they got there. (STAT News)

BioMarin is resubmitting its BLA for gene therapy for hemophilia A, after the FDA rejected it two years ago. The biotech has now submitted Phase III data, in addition to more data from an ongoing Phase I/II dose escalation study. (Endpoints News)